Cryo-Cell International (CCEL) Stock Price, News & Analysis

Company Overview

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Key Stats

• Today's Range: $5.00 to $5.10
• 50-Day Range: $4.80 to $5.52
• 52-Week Range: $4.75 to $9.43
• Volume: 6,885 shs
• Average Volume: 13,100 shs
• Market Capitalization: $40.80 million
• P/E Ratio: 505.51
• Dividend Yield: 11.88%
• Price Target: $8.50
• Consensus Rating: Buy

Cryo-Cell International Stock Analysis - MarketRank™

Cryo-Cell International scored higher than 68% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cryo-Cell International has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cryo-Cell International has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cryo-Cell International is 505.51, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.61.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cryo-Cell International is 505.51, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.43.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.18% of the float of Cryo-Cell International has been sold short.

Short Interest Ratio / Days to Cover

Cryo-Cell International has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cryo-Cell International has recently decreased by 21.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Cryo-Cell International is a leading dividend payer. It pays a dividend yield of 11.88%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Cryo-Cell International does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.18% of the float of Cryo-Cell International has been sold short.

Short Interest Ratio / Days to Cover

Cryo-Cell International has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cryo-Cell International has recently decreased by 21.28%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cryo-Cell International insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.86% of the stock of Cryo-Cell International is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 10.44% of the stock of Cryo-Cell International is held by institutions.

CCEL Stock Analysis - Frequently Asked Questions

How have CCEL shares performed this year?

Cryo-Cell International's stock was trading at $6.50 on January 1st, 2025. Since then, CCEL stock has decreased by 22.3% and is now trading at $5.05.

How were Cryo-Cell International's earnings last quarter?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) released its quarterly earnings results on Tuesday, October, 15th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.11. The company earned $8.07 million during the quarter. Cryo-Cell International had a negative trailing twelve-month return on equity of 1.07% and a net margin of 0.40%.

How do I buy shares of Cryo-Cell International?

Shares of CCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cryo-Cell International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cryo-Cell International investors own include Meta Platforms (META), Alimera Sciences (ALIM), Crescent Biopharma (CBIO), iClick Interactive Asia Group (ICLK), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX) and Aspen Group (ASPU).

Company Calendar

• Last Earnings: 10/15/2024
• Record date for 5/30 Dividend: 5/21/2025
• Dividend Payable: 5/30/2025
• Today: 7/05/2025
• Fiscal Year End: 11/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NYSEAMERICAN:CCEL
• CIK: 862692
• Web: www.cryo-cell.com
• Phone: (813) 749-2100
• Fax: 813-855-4745
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.50
• High Stock Price Target: $8.50
• Low Stock Price Target: $8.50
• Potential Upside/Downside: +68.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.06)
• Trailing P/E Ratio: 505.51
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $400 thousand
• Net Margins: 0.40%
• Pretax Margin: 7.92%
• Return on Equity: -1.07%
• Return on Assets: 0.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.58
• Quick Ratio: 0.54

Sales & Book Value

• Annual Sales: $31.99 million
• Price / Sales: 1.28
• Cash Flow: $0.18 per share
• Price / Cash Flow: 28.18
• Book Value: ($1.64) per share
• Price / Book: -3.08

Miscellaneous

• Outstanding Shares: 8,080,000
• Free Float: 5,103,000
• Market Cap: $40.80 million
• Optionable: Not Optionable
• Beta: 0.64